Marco de Groot
Overview
Explore the profile of Marco de Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
95
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hilberink J, Morsink L, van der Velden W, Mulder A, Hazenberg C, de Groot M, et al.
Transplant Cell Ther
. 2021 Mar;
27(3):246-252.
PMID: 33781523
The predictive value of measurable residual disease (MRD) for survival in acute myeloid leukemia (AML) has been firmly established in younger patients treated with intensive chemotherapy. The value of MRD...
2.
Gorin N, Labopin M, Blaise D, de Groot M, Socie G, Bourhis J, et al.
Cancer
. 2019 Nov;
126(5):1004-1015.
PMID: 31774557
Background: In adult patients with acute myeloid leukemia (AML), a matched sibling donor (MSD) is considered the first choice for an allogeneic transplantation. However, a female donor for a male...
3.
Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa J, van der Helm L, et al.
Leuk Res
. 2019 Apr;
80:33-39.
PMID: 30954622
Therapeutic decision making is often challenging in older AML patients. We collected retrospective data of 355 consecutive AML patients (≥60 years) who were treated with intensive chemotherapy (IC) (n = ...
4.
Pecci A, Klersy C, Gresele P, Lee K, De Rocco D, Bozzi V, et al.
Hum Mutat
. 2013 Nov;
35(2):236-47.
PMID: 24186861
MYH9-related disease (MYH9-RD) is a rare autosomal-dominant disorder caused by mutations in the gene for nonmuscle myosin heavy chain IIA (NMMHC-IIA). MYH9-RD is characterized by a considerable variability in clinical...